Post

New research · Ophthalmology
Annals of hematology · 1d
Case reportAnnals of hematology · 2026

Half-dose glucarpidase: an effective rescue for toxic methotrexate plasma concentrations in a patient with bilateral primary vitreoretinal lymphoma.

Ángela González-Román, Thais Lizondo, Carla Bastida … Dolors Soy
Read paper
OphthalmologyCase report

Half-dose glucarpidase sharply lowered toxic methotrexate levels after high-dose therapy.

Half-dose glucarpidase: an effective rescue for toxic methotrexate plasma concentrations in a patient with bilateral primary vitreoretinal lymphoma.

Ángela González-Román … Dolors Soy
Annals of hematology · 2026
Background

Primary vitreoretinal lymphoma (primary vitreoretinal lymphoma) is a rare, aggressive subtype of central nervous system lymphoma that initially presents in the eye.

Results
94.6%
MTX blood levels dropped sharply after the reduced dose was given
More results

We report the case of a 29-year-old man with bilateral primary vitreoretinal lymphoma receiving treatment with the MATRIX regimen.

During the fourth cycle, the patient developed acute kidney injury following intravenous high-dose methotrexate (3.5 g/m²), despite prophylactic measures including hydration, urinary alkalinization, and folinic acid rescue.

More results

Plasma MTX concentrations remained elevated at 32 µmol/L at 23 hours and 20 µmol/L at 42 hours post-infusion.

Although the standard glucarpidase dose is 50 U/kg, emerging evidence supports the effectiveness of lower doses, which may offer similar clinical benefit while reducing costs.

“
Conclusion

Low-dose glucarpidase (25 U/kg) proved effective and safe in treating high-dose methotrexate-induced nephrotoxicity in this patient, offering a cost-effective alternative in settings with limited availability of rescue agents, emphasizing the need for timely intervention and multidisciplinary coordination.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving